Pharming Group NV reports results for the quarter ended in January - Earnings Summary

Pharming

01/08/2024 07:02

* Pharming Group NV  PHAR.AS  reported quarterly breakeven
results​​ per share for the quarter ended in January, identical
to the same quarter last year.  The mean expectation of
two analysts for the quarter was for earnings of one cent per
share. Wall Street expected results to range from zero cents
to 2 cents per share.
    * Revenue rose 35% to $74.09 million from a year ago;
analysts
expected $74.44 million. 
    * Pharming Group NV's reported EPS for the quarter was
breakeven
results​.
    * The company reported a quarterly loss of $1.22 million.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 6.7%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 5 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the
pharmaceuticals
peer group is also "strong buy"

Wall Street's median 12-month price target for Pharming Group NV
is €1.63 
This summary was machine generated from LSEG data August 1 at
06:02 a.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2024      0.01           0.00           Missed
 Mar. 31 2024      0.01           -0.02          Missed
 Dec. 31 2023      -0.03          0.00           Beat
 Sep. 30 2023      -0.03          0.01           Beat